Pfizer (NYSE: PFE) filed an 8-K with the SEC on 4 August 2026 to report its second-quarter 2026 results. It was a beat-and-raise: adjusted profit and revenue both came in ahead of Wall Street, and the company nudged its full-year revenue outlook higher — even though the headline GAAP line shows a small loss because of a large one-off write-down.

The numbers

• Revenue: $15.03 billion, up just 1% operationally year-over-year — but that beat the roughly $14.4 billion analysts expected. Strip out the fading COVID products (Comirnaty and Paxlovid) and revenue grew 5%; Pfizer's "launched and acquired" products grew 18%.
• Adjusted EPS: $0.77 vs about $0.68 expected — a clear beat.
• GAAP (reported) EPS: a loss of $(0.04) per share — but this reflects $4.3 billion of non-cash intangible-asset impairments (an accounting write-down, not cash going out the door). That's why the "loss" and the healthy adjusted profit sit side by side.
• What drove it: heart drug Eliquis, cancer therapy Padcev, the Vyndaqel family and Lorbrena, partly offset by lower COVID-19 sales.
• Guidance: raised full-year 2026 revenue by $500m at the midpoint to $60.5–$62.5 billion, and reaffirmed adjusted EPS of $2.80–$3.00. It also flagged an extra $2.5 billion of planned cost savings for 2027–2029.

What an 8-K "Item 2.02" is

An 8-K is the form US-listed companies use to tell investors about a material event between their big quarterly (10-Q) and annual (10-K) reports. Item 2.02 — "Results of Operations and Financial Condition" is the specific box a company ticks when it's releasing quarterly earnings. The actual results usually live in an attached press release (an "exhibit"), which the 8-K formally files with the SEC. So when you see a company file an 8-K under Item 2.02, it almost always means: earnings are out.

Why it matters

The story underneath Pfizer's numbers is the transition away from COVID. Total revenue barely grew (1%) because Comirnaty and Paxlovid are shrinking — but the rest of the business grew 5%, and the newer/acquired drugs grew 18%. That's what investors watch: can the base business grow fast enough to replace the COVID windfall? A revenue and adjusted-EPS beat, plus a raised revenue outlook, says the underlying engine is holding up. The big GAAP loss looks alarming but is an accounting impairment (writing down the value of assets Pfizer owns) — it doesn't drain cash and companies exclude it from "adjusted" figures for exactly that reason. None of this tells you where the share price goes; it's about the health of the business.

Beginner takeaway

Pfizer beat on the two numbers markets care about most — adjusted profit and revenue — and raised its revenue guidance, which is generally read as a sign of confidence. The scary-looking GAAP "loss" is a one-off, non-cash write-down, not a sign the company burned cash. When a headline profit and a headline loss appear for the same quarter, the difference is almost always these adjustments — always check which number you're reading.

FAQ

How did Pfizer post a loss but still "beat"? The GAAP loss comes from a $4.3bn non-cash write-down of asset values. Excluding that (and other one-offs), Pfizer earned an adjusted $0.77 a share, which topped estimates.

What's the difference between GAAP and "adjusted" EPS? GAAP follows strict accounting rules and includes one-time items; adjusted (non-GAAP) strips out things management sees as unusual, like impairments or deal costs, to show the underlying run-rate. Both are useful — just know which is which.

Why is total revenue up only 1% if the drugs are growing? COVID products (Comirnaty, Paxlovid) are still declining and drag the total down. Excluding them, revenue grew about 5%.

Does "raised guidance" mean the stock will go up? Not necessarily. Raised guidance signals management confidence, but share prices depend on expectations already priced in and many other factors. This is education, not a prediction.

As of 4 August 2026. Source: official SEC filing — read it directly here. We summarise filings for education and may make errors, so always verify against the official document. Educational content only — not investment advice, not a buy/sell recommendation.